GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Cefepime

Local RX List renal extractBase record retrieved 2026-09-05See the evidence for this drug7 sources available - open source summaries, references and comparisons

Maxipime

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)
Review first - source-specific qualification

Different HD schedules remain source-specific, not interchangeable

The MAXIPIME mirror uses daily maintenance; UCSF describes a post-HD strategy and a separate unstable-schedule alternative.

Before applying: Resolve indication, dialysis timing and local specialist protocol before selecting a regimen; do not average or mix schedules.

Evidence for this qualification

Selected-source qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (7)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Daily post-HD timing is not the same as post-HD-only dosing

Label and institutional sources include daily dosing and post-dialysis-only schedules. Their indication, dialysis frequency, infusion, and exposure assumptions differ.

Before applying: Select one complete locally approved regimen; do not add a daily dose on top of a post-HD-only schedule.

Also check: Daily post-HD timing is not the same as post-HD-only dosing

Rxlist source

GlobalRPh RX List - MAXIPIME

Product / population
Single-agent intravenous cefepime in adults. Label-mirror schedules and UCSF institutional regimens must retain their distinct context.
Renal measure
Cockcroft-Gault CrCl, mL/min; steady-state assumption; separate HD schedule

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Selected sections only; not a complete prescribing monograph or independent clinician approval.

A hosted label mirror is not independent corroboration of its underlying label. Official confirmation remains pending unless a separate official card is shown.

Renal dosing, restrictions and evidence limits

The mirror's intermittent-HD schedule is 1 g on day 1, then 500 mg every 24 hours, except febrile neutropenia uses 1 g every 24 hours. Administer after HD on dialysis days. Its usual IV infusion is approximately 30 minutes.

Its non-dialysis table uses Cockcroft-Gault CrCl and assumes steady-state renal function. The separately imported UCSF dialysis and extended-infusion protocols differ; do not combine elements into an unsupported hybrid schedule.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/maxipime-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

GlobalRPh RX List - MAXIPIME

Authored v5.8; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

A regimen is reported in selected content

Read the source and its limits

UCSF cefepime - dated institutional recheck

Authored v5.8; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

A regimen is reported in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Maxipime

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult IV cefepime. Columns below correspond to the original usual regimen, not interchangeable infection choices.

Renal method: CrCl by Cockcroft-Gault using steady-state serum creatinine, mL/min.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - MAXIPIME

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Dialysis evidence: A regimen is reported in selected content

Single-agent intravenous cefepime in adults. Label-mirror schedules and UCSF institutional regimens must retain their distinct context.

Renal method: Cockcroft-Gault CrCl, mL/min; steady-state assumption; separate HD schedule
Retrieved: 2026-09-10

Read local renal resultOpen original reference
Professional guidance

UCSF - cefepime: short infusion and dialysis

Adult IV cefepime; short infusion, selected extended infusion, IHD and CVVHD.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

Stanford - cefepime dialysis strategies

Adults; cefepime IV. Guide page 2, IHD/CRRT columns.

Renal method: IHD assumes three sessions weekly; CRRT-specific column.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

Nebraska Medicine - cefepime by CVVHD dialysate flow

Adults; CVVHD only. Source PDF page 5.

Renal method: Dialysate flow in L/hour, not a generic CrCl band.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF cefepime - dated institutional recheck

Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.

Dialysis evidence: A regimen is reported in selected content

Single-agent intravenous cefepime in adults. Label-mirror schedules and UCSF institutional regimens must retain their distinct context.

Renal method: CrCl in mL/min; equation not specified on the selected UCSF page
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Different HD schedules remain source-specific, not interchangeable

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 2 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

dialysis setting

Daily post-HD timing is not the same as post-HD-only dosing

Label and institutional sources include daily dosing and post-dialysis-only schedules. Their indication, dialysis frequency, infusion, and exposure assumptions differ.

How to use this: Select one complete locally approved regimen; do not add a daily dose on top of a post-HD-only schedule.

GlobalRPh RX List - MaxipimeUCSF - cefepime: short infusion and dialysisStanford - cefepime dialysis strategies

Source difference identified; final patient-specific adjudication required.

institutional versus label dialysis strategy

Different HD schedules remain source-specific, not interchangeable

The MAXIPIME mirror uses daily maintenance; UCSF describes a post-HD strategy and a separate unstable-schedule alternative.

How to use this: Resolve indication, dialysis timing and local specialist protocol before selecting a regimen; do not average or mix schedules.

GlobalRPh RX List - MAXIPIMEUCSF cefepime - dated institutional recheckEXBLIFEP - cefepime and enmetazobactam injection

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - MaxipimeGlobalRPh RX List - MAXIPIMEUCSF - cefepime: short infusion and dialysisStanford - cefepime dialysis strategiesNebraska Medicine - cefepime by CVVHD dialysate flowUCSF cefepime - dated institutional recheck
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The source introductory threshold is rendered =60; the source table is preserved separately. This is not a newly verified label transcription.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/cefepime/

Usual Dosing (Adults)

Mild to moderate: 500 mg to 1 gram IV every 12 hours. Moderate to severe: 1 to 2 grams IV every 12 hours. Febrile neutropenic: 2 grams IV every 8 hours.

MAXIPIME recommended schedule, creatinine clearance >60 mL/min:

IndicationDoseIntervalDuration
Moderate to severe pneumonia due to S. pneumoniae (including concurrent bacteremia), P. aeruginosa, K. pneumoniae, or Enterobacter1 to 2 g IVEvery 12 hours10 days
Empiric therapy for febrile neutropenia2 g IVEvery 8 hours7 days or until resolution of neutropenia
Mild to moderate uncomplicated or complicated urinary tract infection, including pyelonephritis, due to E. coli, K. pneumoniae or P. mirabilis (including concurrent bacteremia)0.5 to 1 g IV or IMEvery 12 hours7 to 10 days
Severe uncomplicated or complicated urinary tract infection, including pyelonephritis, due to E. coli or K. pneumoniae (including concurrent bacteremia)2 g IVEvery 12 hours10 days
Moderate to severe uncomplicated skin and skin structure infection due to S. aureus or S. pyogenes2 g IVEvery 12 hours10 days
Complicated intra-abdominal infection with metronidazole, due to E. coli, viridans group streptococci, P. aeruginosa, K. pneumoniae, Enterobacter or B. fragilis2 g IVEvery 12 hours7 to 10 days

For febrile neutropenia, if fever resolves but neutropenia persists for more than 7 days, the need for continued antimicrobial therapy should be re-evaluated frequently. IM administration is indicated only for mild to moderate urinary tract infections due to E. coli when IM administration is considered appropriate.

Pediatric patients 2 months to 16 years weighing up to 40 kg: 50 mg/kg/dose every 12 hours for the indications and durations above; every 8 hours for febrile neutropenia. Do not exceed the recommended adult dose.

GRPH-cefepime-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

Summary:

CrCl (mL/min)Source recommendation
>60No change
30 to 60500 mg to 2 g every 24 hours; neutropenic: 2 g every 12 hours
11 to 29500 mg to 1 g every 24 hours; neutropenic: 2 g every 24 hours
<11250 to 500 mg every 24 hours; neutropenic: 1 g every 24 hours

The source introduction renders the impairment threshold as "creatinine clearance =60 mL/min". It states that the dose should compensate for slower renal elimination and that the initial dose is the same as in normal renal function except in patients undergoing hemodialysis.

Recommended maintenance schedules by the usual normal-function regimen:

CrCl or treatmentUsual 500 mg every 12 hoursUsual 1 g every 12 hoursUsual 2 g every 12 hoursUsual 2 g every 8 hours
>60 mL/min500 mg every 12 hours1 g every 12 hours2 g every 12 hours2 g every 8 hours
30 to 60 mL/min500 mg every 24 hours1 g every 24 hours2 g every 24 hours2 g every 12 hours
11 to 29 mL/min500 mg every 24 hours500 mg every 24 hours1 g every 24 hours2 g every 24 hours
<11 mL/min250 mg every 24 hours250 mg every 24 hours500 mg every 24 hours1 g every 24 hours
CAPD500 mg every 48 hours1 g every 48 hours2 g every 48 hours2 g every 48 hours
GRPH-cefepime-02 · Source section: Renal DosingRenal section finder

Hemodialysis

Approximately 68% of the cefepime present in the body at the start of dialysis is removed during a 3-hour dialysis period. Recommended dose: 1 g on day 1, followed by 500 mg every 24 hours for all infections except febrile neutropenia, for which 1 g every 24 hours is recommended. Administer at the same time each day and following completion of hemodialysis on dialysis days.

GRPH-cefepime-03 · Source section: HemodialysisRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Maxipime

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult IV cefepime. Columns below correspond to the original usual regimen, not interchangeable infection choices.

Renal method: CrCl by Cockcroft-Gault using steady-state serum creatinine, mL/min.
Source date: Revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Maintenance schedules (all doses IV; intervals in hours):

CrClUsual 500 mg q12hUsual 1 g q12hUsual 2 g q12hUsual 2 g q8h
30-60500 mg q24h1 g q24h2 g q24h2 g q12h
11-29500 mg q24h500 mg q24h1 g q24h2 g q24h
Below 11250 mg q24h250 mg q24h500 mg q24h1 g q24h
CAPD500 mg q48h1 g q48h2 g q48h2 g q48h

Hemodialysis: 1 g on day 1, then 500 mg every 24 hours, except febrile neutropenia requires 1 g every 24 hours. Give after dialysis on dialysis days. Infuse over approximately 30 minutes. The initial dose otherwise matches the normal-function regimen.

RDM33-rxlist-cefepime-C1 · Source locator: Adult renal dosage, Table 2 and footnotes; IV administration.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/maxipime-drug/
Retrieved
2026-09-07
Renal-function method
CrCl by Cockcroft-Gault using steady-state serum creatinine, mL/min.
Source date/version
Revision date not established in selected retrieval.
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
bfa36dc079868a0813aa7a954507b225c6acf073b36fb8a0c6b27b5cf31409bf
Rxlist

GlobalRPh RX List - MAXIPIME

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Single-agent intravenous cefepime in adults. Label-mirror schedules and UCSF institutional regimens must retain their distinct context.

Renal method: Cockcroft-Gault CrCl, mL/min; steady-state assumption; separate HD schedule
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Dialysis evidence: A regimen is reported in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The mirror's intermittent-HD schedule is 1 g on day 1, then 500 mg every 24 hours, except febrile neutropenia uses 1 g every 24 hours. Administer after HD on dialysis days. Its usual IV infusion is approximately 30 minutes.

Its non-dialysis table uses Cockcroft-Gault CrCl and assumes steady-state renal function. The separately imported UCSF dialysis and extended-infusion protocols differ; do not combine elements into an unsupported hybrid schedule.

RDM58-rxlist-cefepime-a79c7e83da-C1 · Source locator: Dosage Adjustments: Table 2 and HD paragraph; IV preparation

Source-specific limits

Selected sections only; not a complete prescribing monograph or independent clinician approval.

A hosted label mirror is not independent corroboration of its underlying label. Official confirmation remains pending unless a separate official card is shown.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/maxipime-drug/
Retrieved
2026-09-10
Renal-function method
Cockcroft-Gault CrCl, mL/min; steady-state assumption; separate HD schedule
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
7ee8e7b82b63b7f6fd0a0137fff964aebdb9284387e6f54da3affaa8eee9f4d7
Separate professional-source layer

University and professional protocols

Professional

UCSF - cefepime: short infusion and dialysis

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adult IV cefepime; short infusion, selected extended infusion, IHD and CVVHD.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Limits that apply to these rows

These are separately selected institutional strategies; do not merge short-infusion, extended-infusion or dialysis instructions.

Non-severe infection - IV short infusion
CrCl, mL/minSource-specific dose / instruction
>602 g every 12 hours
30-602 g every 24 hours
10-291 g every 24 hours
<10500 mg every 24 hours
Severe infection including neutropenic fever, meningitis or Pseudomonas - IV
CrCl, mL/minSource-specific dose / instruction
>602 g every 8 hours
30-602 g every 12 hours
10-292 g every 24 hours
<101 g every 24 hours
Separate specialist-selected extended infusion
CrCl, mL/minSource-specific dose / instruction
>602 g over 4 hours every 8 hours
30-602 g over 4 hours every 12 hours
<30Use short infusion, not this extended-infusion pathway

2 g loading dose over 30 minutes; start maintenance 4 hours after loading. Extended-infusion evidence in meningitis is limited.

Dialysis guidance - separate source-specific schedules
Cefepime dialysis
Dialysis setting / indicationSource-specific schedule
IHD2 g initially and following dialysis
IHD with unstable schedule - alternative1 g initially, then each evening
CVVHD1 g every 8 hours
Read the retained text before reformatting

All doses below are IV. For CrCl >60 / 30-60 / 10-29 / <10 mL/min, respectively:

  • Non-severe infection: 2 g every 12 hours / 2 g daily / 1 g daily / 500 mg daily.
  • Severe infection, including neutropenic fever, meningitis or Pseudomonas: 2 g every 8 hours / 2 g every 12 hours / 2 g daily / 1 g daily.

Intermittent HD: 2 g initially and following dialysis. When the dialysis schedule is unstable, the alternative is 1 g initially, then every evening. CVVHD: 1 g every 8 hours.

A separate specialist-selected extended-infusion regimen uses a 2 g loading dose over 30 minutes, then 2 g over 4 hours every 8 hours when CrCl >60 or every 12 hours at 30-60. Start maintenance 4 hours after loading; use short infusion below 30. Meningitis extended-infusion evidence is limited.

RDM30-001-cefepime-1 · Source locator: UCSF - cefepime: short infusion and dialysis; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/cefepime
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
fa13011553cd6ab8659b703a07556bf290d1da14a5e4402763f58d55f71de631
Professional

Stanford - cefepime dialysis strategies

Open original reference

Open / share this exact local source

Stanford Health Care Antimicrobial Safety and Sustainability · Adults; cefepime IV. Guide page 2, IHD/CRRT columns.

Renal method: IHD assumes three sessions weekly; CRRT-specific column.
Source date: Current retrieved guide; see source document for revision history.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

In the Stanford guide, IHD dosing is 0.5-1 g IV daily, after HD on treatment days; 2 g after each HD session is an alternative. CRRT uses a 2 g load followed by 1 g every 8 hours as a 4-hour infusion. These are separate dialysis options, not additive doses.

RDM30-059-cefepime-1 · Source locator: Stanford - cefepime dialysis strategies; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://med.stanford.edu/content/dam/sm/bugsanddrugs/documents/antimicrobial-dosing-protocols/SHC-ABX-Dosing-Guide.pdf
Retrieved
2026-09-05
Renal-function method
IHD assumes three sessions weekly; CRRT-specific column.
Source date/version
Current retrieved guide; see source document for revision history.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
501b0f98374dd0e4d931f9d086d033f979c0f00d674b971de0a4585b0f8c1206
Professional

Nebraska Medicine - cefepime by CVVHD dialysate flow

Open original reference

Open / share this exact local source

University of Nebraska Medical Center / Nebraska Medicine · Adults; CVVHD only. Source PDF page 5.

Renal method: Dialysate flow in L/hour, not a generic CrCl band.
Source date: 2023 CRRT/PIRRT reference.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

After a 2 g IV load, standard-infection CVVHD dosing is 1 g every 8 hours at 1 L/hour; 1 g every 6 hours at 2 L/hour; and 1 g every 6 hours or 2 g every 8 hours at 3-4 L/hour. The neutropenic-fever row instead lists 2 g every 12 hours at 1-2 L/hour and 2 g every 8 hours at 3-4 L/hour. Reassess when therapy stops.

RDM30-062-cefepime-1 · Source locator: Nebraska Medicine - cefepime by CVVHD dialysate flow; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://www.unmc.edu/intmed/_documents/id/asp/final_crrt_pirrt_abxrecommendations_2023.pdf
Retrieved
2026-09-05
Renal-function method
Dialysate flow in L/hour, not a generic CrCl band.
Source date/version
2023 CRRT/PIRRT reference.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
28eb23684864d4cd1bbe46a3d0f2995640b73193a7d12cbec869e0598f0693f0
Professional

UCSF cefepime - dated institutional recheck

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Single-agent intravenous cefepime in adults. Label-mirror schedules and UCSF institutional regimens must retain their distinct context.

Renal method: CrCl in mL/min; equation not specified on the selected UCSF page
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.

Dialysis evidence: A regimen is reported in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

UCSF prefers short infusion. For selected patients with specialist/pharmacy recommendation, its extended-infusion maintenance is 2 g every 8 hours at CrCl >60 or every 12 hours at 30-60, infused over 4 hours; below 30 it directs use of short infusion. Loading is 2 g over 30 minutes unless already receiving short-infusion cefepime; maintenance starts four hours later. Meningitis data are limited.

For intermittent HD it lists 2 g initially and post-HD; an unstable-schedule alternative is 1 g initially then each evening. These are institutional regimens, not a manufacturer-label replacement or a universal dialysis schedule.

RDM58-professional-cefepime-c9ffc869f7-C1 · Source locator: Adult non-dialysis short/extended infusion; Intermittent & Continuous Hemodialysis table

Source-specific limits

Selected sections only; not a complete prescribing monograph or independent clinician approval.

Named institutional guidance, not manufacturer labeling or a universal dosing recommendation. Apply only after local specialist review of patient and treatment context.

Source identity and provenance
Source family
professional_guidance
Source
https://idmp.ucsf.edu/content/cefepime
Retrieved
2026-09-10
Renal-function method
CrCl in mL/min; equation not specified on the selected UCSF page
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
bf93e6eab1f98839cc03a3dc1ce1a317d9a6c88183a6c345e2783834e3679ab0

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 2 RX List, 4 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/cefepime/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
44b0fbc35bb32a03084d99f24367963ae43ce3102090b436122f158cf6653ec8
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report